

amended (5 U.S.C. Appendix 2), notice is hereby given of the following National Institute of General Medical Sciences, Special Emphasis Panel (SEP) meeting:

*Committee Name:* Special Emphasis Panel—Anesthesiology.  
*Date:* November 14, 1996.  
*Time:* 7:00 a.m.—adjournment.  
*Place:* Penn Tower Hotel, Civic Center Blvd. at 34th Street, Philadelphia, PA 19104.  
*Contact Person:* Irene A. Eckstrand, Ph.D., 45 Center Drive, Room 2AS-25P, Bethesda, MD 20892-6200, 301-594-0943.  
*Purpose:* To review an Anesthesiology application.

This notice is being published less than 15 days prior to the above meeting due to the urgent need to meet timing limitations imposed by the review and funding cycle.

This meeting will be closed in accordance with the provisions set forth in secs. 552b(c)(4) and 552b(c)(6), Title 5, U.S.C. The discussions of these applications could reveal confidential trade secrets or commercial property such as patentable material and personal information concerning individuals associated with the applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

(Catalog of Federal Domestic Assistance Program Nos. 93.821, Biophysics and Physiological Sciences; 93.859, Pharmacological Sciences; 93.862, Genetics Research; 93.863, Cellular and Molecular Basis of Disease Research; 93.880, Minority Access Research Careers [MARC]; and 93.375, Minority Biomedical Research Support [MBRS])

*Dated:* October 28, 1996.  
Paula N. Hayes,  
*Acting Committee Management Officer, NIH.*  
[FR Doc. 96-28265 Filed 11-1-96; 8:45 am]  
**BILLING CODE 4140-01-M**

### National Institute of General Medical Sciences; Notice of Closed Meeting

Pursuant to Section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following advisory committee meeting of the National Institute of General Medical Sciences:

*Committee Name:* MARC (Minority Access to Research Careers) Special Emphasis Panel.  
*Date:* December 3, 1996.  
*Time:* 9:30 a.m.—adjournment.  
*Place:* Telephone Conference, 45 Center Drive, Bethesda, MD 20892-6200.  
*Contact Person:* Richard I. Martinez, Ph.D., Scientific Review Administrator, NIGMS, 45 Center Drive, Room 1AS-19G, Bethesda, MD 20892-6200, 301-594-2849.

*Purpose:* To review cooperative agreement (U13) applications submitted in response to the RFA.

This meeting will be closed in accordance with the provisions set forth in secs. 552b(c)(4) and 552b(c)(6), Title 5, U.S.C. The

discussions of these applications could reveal confidential trade secrets or commercial property such as patentable material and personal information concerning individuals associated with the applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

(Catalog of Federal Domestic Assistance Program Nos. 93.821, Biophysics and Physiological Sciences; 93.859, Pharmacological Sciences; 93.862, Genetics Research; 93.863, Cellular and Molecular Basis of Disease Research; 93.880, Minority Access Research Careers [MARC]; and 93.375, Minority Biomedical Research Support [MBRS])

*Dated:* October 28, 1996.  
Paula N. Hayes,  
*Acting Committee Management Officer, NIH.*  
[FR Doc. 96-28271 Filed 11-1-96; 8:45 am]  
**BILLING CODE 4140-01-M**

### National Institute of Allergy and Infectious Diseases; Notice of Closed Meeting

Pursuant to Section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following National Institute of Allergy and Infectious Diseases Special Emphasis Panel (SEP) meeting:

*Name of SEP:* Preclinical Evaluation of Therapies for Cryptosporidium Parvum Infections.

*Date:* December 9, 1996.  
*Time:* 8:30 a.m.  
*Place:* Solar Bldg., Rm. 1A01, 6003 Executive Boulevard, Bethesda, MD 20892-7610, (301) 402-0747.

*Contact Person:* Dr. Sayeed Quraishi, Scientific Review Adm., 6003 Executive Boulevard, Solar Bldg., Room 4C22, Bethesda, MD 20892-7610, (301) 496-7465.  
*Purpose/Agenda:* To evaluate contract proposals.

The meeting will be closed in accordance with the provisions set forth in secs. 552b(c)(4) and 552b(c)(6), Title 5, U.S.C. Applications and/or proposals and the discussions could reveal confidential trade secrets or commercial property such as patentable material and personal information concerning individuals associated with the applications and/or proposals, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

(Catalog of Federal Domestic Assistance Programs Nos. 93.855, Immunology, Allergic and Immunologic Diseases Research; 93.856, Microbiology and Infectious Diseases Research, National Institutes of Health)

*Dated:* October 28, 1996.  
Paula N. Hayes,  
*Acting Committee Management Officer, NIH.*  
[FR Doc. 96-28272 Filed 11-1-96; 8:45 am]  
**BILLING CODE 4140-01-M**

### Recombinant DNA Advisory Committee; Notice of Meeting

Pursuant to Public Law 92-463, notice is hereby given of a meeting of the Recombinant DNA Advisory Committee on December 9, 1996. The meeting will be held at the National Institutes of Health, Building 31C, 6th Floor, Conference Room 10, 9000 Rockville Pike, Bethesda, Maryland 20892, starting on December 9, 1996, at approximately 9 a.m., and will adjourn at approximately 5 p.m. The meeting will be open to the public to discuss Proposed Actions under the NIH Guidelines for Research Involving Recombinant DNA Molecules (59 FR 34496) and other matters to be considered by the Committee. The Proposed Actions to be discussed will follow this notice of meeting. Attendance by the public will be limited to space available. Members of the public wishing to speak at this meeting may be given such opportunity at the discretion of the Chair.

Ms. Debra W. Knorr, Biotechnology Program Advisor, Office of Recombinant DNA Activities, National Institutes of Health, MSC 7010, 6000 Executive Boulevard, Suite 302, Bethesda, Maryland 20892-7010, Phone (301) 496-9838, FAX (301) 496-9839, will provide materials to be discussed at this meeting, roster of committee members, and substantive program information. Individuals who plan to attend and need special assistance, such as sign language interpretation or other reasonable accommodations, should contact Ms. Knorr in advance of the meeting. A summary of the meeting will be available at a later date.

OMB's "Mandatory Information Requirements for Federal Assistance Program Announcements" (45 FR 39592, June 11, 1980) requires a statement concerning the official government programs contained in the Catalog of Federal Domestic Assistance. Normally NIH lists in its announcements the number and title of affected individual programs for the guidance of the public. Because the guidance in this notice covers not only virtually every NIH program but also essentially every Federal research program in which DNA recombinant molecule techniques could be used, it has been determined not to be cost effective or in the public interest to attempt to list these programs.

Such a list would likely require several additional pages. In addition, NIH could not be certain that every Federal program would be included as many Federal agencies, as well as private organizations, both national and

international, have elected to follow the NIH Guidelines. In lieu of the individual program listing, NIH invites readers to direct questions to the information address above about whether individual programs listed in the Catalog of Federal Domestic Assistance are affected.

Dated: October 28, 1996.

Paula N. Hayes,

*Acting Committee Management Officer, NIH.*  
[FR Doc. 96-28270 Filed 11-1-96; 8:45 am]

BILLING CODE 4140-01-M

## Substance Abuse and Mental Health Services Administration

### Current List of Laboratories Which Meet Minimum Standards To Engage in Urine Drug Testing for Federal Agencies, and Laboratories That Have Withdrawn From the Program

**AGENCY:** Substance Abuse and Mental Health Services Administration, HHS (Formerly: National Institute on Drug Abuse, ADAMHA, HHS).

**ACTION:** Notice.

**SUMMARY:** The Department of Health and Human Services notifies Federal agencies of the laboratories currently certified to meet standards of Subpart C of Mandatory Guidelines for Federal Workplace Drug Testing Programs (59 FR 29916, 29925). A similar notice listing all currently certified laboratories will be published during the first week of each month, and updated to include laboratories which subsequently apply for and complete the certification process. If any listed laboratory's certification is totally suspended or revoked, the laboratory will be omitted from updated lists until such time as it is restored to full certification under the Guidelines.

If any laboratory has withdrawn from the National Laboratory Certification Program during the past month, it will be identified as such at the end of the current list of certified laboratories, and will be omitted from the monthly listing thereafter.

**FOR FURTHER INFORMATION CONTACT:** Mrs. Giselle Hersh, Division of Workplace Programs, Room 13A-54, 5600 Fishers Lane, Rockville, Maryland 20857; Tel.: (301) 443-6014.

**SUPPLEMENTARY INFORMATION:** Mandatory Guidelines for Federal Workplace Drug Testing were developed in accordance with Executive Order 12564 and section 503 of Pub. L. 100-71. Subpart C of the Guidelines, "Certification of Laboratories Engaged in Urine Drug Testing for Federal

Agencies," sets strict standards which laboratories must meet in order to conduct urine drug testing for Federal agencies. To become certified an applicant laboratory must undergo three rounds of performance testing plus an on-site inspection. To maintain that certification a laboratory must participate in a quarterly performance testing program plus periodic, on-site inspections.

Laboratories which claim to be in the applicant stage of certification are not to be considered as meeting the minimum requirements expressed in the HHS Guidelines. A laboratory must have its letter of certification from SAMHSA, HHS (formerly: HHS/NIDA) which attests that it has met minimum standards.

In accordance with Subpart C of the Guidelines, the following laboratories meet the minimum standards set forth in the Guidelines:

Aegis Analytical Laboratories, Inc., 624 Grassmere Park Rd., Suite 21, Nashville, TN 37211, 615-331-5300  
Alabama Reference Laboratories, Inc., 543 South Hull St., Montgomery, AL 36103, 800-541-4931 / 334-263-5745  
American Medical Laboratories, Inc., 14225 Newbrook Dr., Chantilly, VA 22021, 703-802-6900  
Associated Pathologists Laboratories, Inc., 4230 South Burnham Ave., Suite 250, Las Vegas, NV 89119-5412, 702-733-7866 / 800-433-2750  
Associated Regional and University Pathologists, Inc. (ARUP), 500 Chipeta Way, Salt Lake City, UT 84108, 801-583-2787 / 800-242-2787  
Baptist Medical Center—Toxicology Laboratory, 9601 I-630, Exit 7, Little Rock, AR 72205-7299, 501-227-2783 (formerly: Forensic Toxicology Laboratory Baptist Medical Center)  
Bayshore Clinical Laboratory, 4555 W. Schroeder Dr., Brown Deer, WI 53223, 414-355-4444 / 800-877-7016  
Cedars Medical Center, Department of Pathology, 1400 Northwest 12th Ave., Miami, FL 33136, 305-325-5784  
Centinela Hospital Airport Toxicology Laboratory, 9601 S. Sepulveda Blvd., Los Angeles, CA 90045, 310-215-6020  
Clinical Reference Lab, 8433 Quivira Rd., Lenexa, KS 66215-2802, 800-445-6917  
CompuChem Laboratories, Inc., 1904 Alexander Drive, Research Triangle Park, NC 27709, 919-549-8263 / 800-833-3984 (formerly: CompuChem Laboratories, Inc., A Subsidiary of Roche Biomedical Laboratory, Roche CompuChem Laboratories, Inc., A Member of the Roche Group)  
CORNING Clinical Laboratories, 4771 Regent Blvd., Irving, TX 75063, 800-526-0947 (formerly: Damon Clinical Laboratories, Damon/MetPath)  
CORNING Clinical Laboratories, 875 Greentree Rd., 4 Parkway Ctr., Pittsburgh, PA 15220-3610, 800-284-7515 (formerly: Med-Chek Laboratories, Inc., Med-Chek/Damon, MetPath Laboratories)

CORNING Clinical Laboratories, 4444 Giddings Road, Auburn Hills, MI 48326, 800-444-0106 / 810-373-9120 (formerly: HealthCare/Preferred Laboratories, HealthCare/MetPath)  
CORNING Clinical Laboratories Inc., 1355 Mittel Blvd., Wood Dale, IL 60191, 630-595-3888 (formerly: MetPath, Inc., CORNING MetPath Clinical Laboratories)  
CORNING Clinical Laboratories, South Central Division, 2320 Schuetz Rd., St. Louis, MO 63146, 800-288-7293 (formerly: Metropolitan Reference Laboratories, Inc.)  
CORNING Clinical Laboratory, One Malcolm Ave., Teterboro, NJ 07608, 201-393-5000 (formerly: MetPath, Inc., CORNING MetPath Clinical Laboratories)  
CORNING National Center for Forensic Science, 1901 Sulphur Spring Rd., Baltimore, MD 21227, 410-536-1485 / 800-522-9235, (formerly: Maryland Medical Laboratory, Inc., National Center for Forensic Science)  
CORNING Clinical Laboratories, 7470-A Mission Valley Rd., San Diego, CA 92108-4406, 800-446-4728 / 619-686-3200 (formerly: Nichols Institute, Nichols Institute Substance Abuse Testing (NISAT), CORNING Nichols Institute)  
Cox Health Systems, Department of Toxicology, 1423 North Jefferson Ave., Springfield, MO 65802, 800-876-3652 / 417-269-3093 (formerly: Cox Medical Centers)  
Dept. of the Navy, Navy Drug Screening Laboratory, Great Lakes, IL, P.O. Box 88-6819, Great Lakes, IL 60088-6819, 847-688-2045 / 847-688-4171  
Diagnostic Services Inc., dba DSI, 4048 Evans Ave., Suite 301, Fort Myers, FL 33901, 941-418-4700 / 800-735-5416  
Doctors Laboratory, Inc., P.O. Box 2658, 2906 Julia Dr., Valdosta, GA 31604, 912-244-4468  
DrugProof, Division of Dynacare/Laboratory of Pathology, LLC, 1229 Madison St., Suite 500, Nordstrom Medical Tower, Seattle, WA 98104, 800-898-0180 / 206-386-2672 (formerly: Laboratory of Pathology of Seattle, Inc., DrugProof, Division of Laboratory of Pathology of Seattle, Inc.)  
DrugScan, Inc., P.O. Box 2969, 1119 Mearns Rd., Warminster, PA 18974, 215-674-9310  
ElSohly Laboratories, Inc., 5 Industrial Park Dr., Oxford, MS 38655, 601-236-2609  
General Medical Laboratories, 36 South Brooks St., Madison, WI 53715, 608-267-6267  
Harrison Laboratories, Inc., 9930 W. Highway 80, Midland, TX 79706, 800-725-3784 / 915-563-3300 (formerly: Harrison & Associates Forensic Laboratories)  
Jewish Hospital of Cincinnati, Inc., 3200 Burnet Ave., Cincinnati, OH 45229, 513-569-2051  
LabOne, Inc., 8915 Lenexa Dr., Overland Park, Kansas 66214, 913-888-3927 / 800-728-4064 (formerly: Center for Laboratory Services, a Division of LabOne, Inc.)  
Laboratory Corporation of America Holdings, 69 First Ave., Raritan, NJ 08869, 800-437-4986, (Formerly: Roche Biomedical Laboratories, Inc.)  
Laboratory Specialists, Inc., 113 Jarrell Dr., Belle Chasse, LA 70037, 504-392-7961  
Marshfield Laboratories, Forensic Toxicology Laboratory, 1000 North Oak Ave.,